Now showing items 1-3 of 3

    • Developing drugs for developing countries. 

      Ridley, David B; Grabowski, Henry G; Moe, Jeffrey L (Health Aff (Millwood), 2006-03)
      Infectious and parasitic diseases create enormous health burdens, but because most of the people suffering from these diseases are poor, little is invested in developing treatments. We propose that developers of treatments ...
    • Priorities for the Priority Review Voucher. 

      Ridley, David B (Am J Trop Med Hyg, 2017-01-11)
      The U.S. Congress created the priority review voucher program in 2007 to encourage development of drugs for neglected diseases. Under the voucher program, the developer of a drug for a neglected or rare pediatric disease ...
    • Spending on postapproval drug safety. 

      Ridley, David B; Kramer, Judith M; Tilson, Hugh H; Grabowski, Henry G; Schulman, Kevin A (Health Aff (Millwood), 2006-03)
      Withdrawals of high-profile pharmaceuticals have focused attention on post-approval safety surveillance. There have been no systematic assessments of spending on postapproval safety. We surveyed drug manufacturers regarding ...